Case Report
Copyright ©The Author(s) 2022.
World J Clin Cases. Sep 6, 2022; 10(25): 9104-9111
Published online Sep 6, 2022. doi: 10.12998/wjcc.v10.i25.9104
Table 1 Timeline of management
Time (day)
Event
1Outpatient evaluation
4Hospitalization
6Found liver mass by CT
11PET-CT
13Core needle biopsy of the liver mass
15Cervical lymph node biopsy
25Surgery
36Discharge
Table 2 Biliary adenofibroma with malignant transformation of the liver, review of the literature
No.
Ref.
Age
Sex
Tumor location
Size (cm)
Treatment
Ki67, %
p53
Outcome
Additional information
1Akin et al[8], 200225MRight hepatic lobe20Right hepatectomyNANAHepatic recurrence and pulmonary metastasis after 3 yr
2Kai et al[12], 201240MRight hepatic lobe7Right hepatectomy5-10NANo recurrence at 8-mo follow-up
3Nguyen et al[13], 201253FSegment IVb6.5Resection of segments III/IVNANANo recurrence after 12 mo
4Tsutsui et al[5], 201469FSegment VI3.5Partial hepatectomy10-15Focally positiveNo recurrence at 4-yr follow-upDysplastic changes
5Thompson et al[4], 201671MLeft hepatic lobe14.5Left hepatectomy NANANo recurrence of liver tumor for 9 yrModeratlely-differentiated adenocarcinoma
6Thompson et al[4], 201671MCaudate lobe6.3Codate lobectomyNANANo recurrence at 1-mo follow-upWell-differentiated adenocarcinoma
7Godambe et al[6], 201671FSegments II, III and IVa5.7Left hepatectomy 50PositiveNAMicroinvasive carcinoma
8Thai et al[14], 201677MSegment II4Left hepatectomy NANANACholangiocarcinoma arising from BAF
9Kaminsky et al[2], 201737FSegment V4.5Partial hepatectomy50NegativeNo recurrence at 4-mo follow-upCholangiocarcinoma arising from BAF
10Chua et al[7], 201866FSegment IVb6Wedge resection 2PositiveNo recurrence at 4-mo follow-upCholangiocarcinoma arising from BAF
11Sturm et al[15], 201963FSegment IVa6.3Left hepatectomy20-30Focally positiveNo recurrence at 24-mo follow-up
12Alshbib et al[9], 202263MSegments IVb and V15.5Resection of segments IVb and V25WeakHepatic recurrence 3 mo
13Current report51FSegments VII and VIII7.5Partial hepatectomy5NegativeNo recurrence at 12-mo follow-up